- Home
- QNCX vs KRON Comparison
QNCX vs KRON Comparison
Compare QNCX & KRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- KRON
- Stock Information
- Founded
- QNCX 2012
- KRON 2017
- Country
- QNCX United States
- KRON United States
- Employees
- QNCX N/A
- KRON N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- KRON Medicinal Chemicals and Botanical Products
- Sector
- QNCX Health Care
- KRON Health Care
- Exchange
- QNCX Nasdaq
- KRON Nasdaq
- Market Cap
- QNCX 44.0M
- KRON 54.4M
- IPO Year
- QNCX 2019
- KRON 2020
- Fundamental
- Price
- QNCX $1.03
- KRON $0.73
- Analyst Decision
- QNCX Strong Buy
- KRON Buy
- Analyst Count
- QNCX 5
- KRON 3
- Target Price
- QNCX $8.00
- KRON $1.63
- AVG Volume (30 Days)
- QNCX 511.8K
- KRON 792.2K
- Earning Date
- QNCX 05-16-2025
- KRON 05-20-2025
- Dividend Yield
- QNCX N/A
- KRON N/A
- EPS Growth
- QNCX N/A
- KRON N/A
- EPS
- QNCX N/A
- KRON N/A
- Revenue
- QNCX N/A
- KRON $9,848,000.00
- Revenue This Year
- QNCX N/A
- KRON N/A
- Revenue Next Year
- QNCX N/A
- KRON N/A
- P/E Ratio
- QNCX N/A
- KRON N/A
- Revenue Growth
- QNCX N/A
- KRON 56.62
- 52 Week Low
- QNCX $0.51
- KRON $0.67
- 52 Week High
- QNCX $2.45
- KRON $1.60
- Technical
- Relative Strength Index (RSI)
- QNCX 38.67
- KRON 36.73
- Support Level
- QNCX $0.98
- KRON $0.67
- Resistance Level
- QNCX $1.16
- KRON $0.76
- Average True Range (ATR)
- QNCX 0.09
- KRON 0.05
- MACD
- QNCX 0.01
- KRON -0.01
- Stochastic Oscillator
- QNCX 22.22
- KRON 22.57
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.